Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, Retinoids in leukemia and cellular processes, and Colorectal Cancer Surgical Treatments.
Epidemiology, clinical features, and molecular basis of <i>TTMV</i> :: <i>RARA</i> -driven acute promyelocytic leukemia
Cystine-Modified Lignin–Copper Coordination Nanocarriers Improve the Therapeutic Efficacy of Tyrosine Kinase Inhibition via Cuproptosis
[ARTICLE WITHDRAWN] Shenfu Injection Alleviates Lipopolysaccharide-Induced Septic Acute Kidney Injury by Regulating the Nrf2/NF-<i>κ</i> B Axis
Glymphatic system dysfunction in pediatric acute lymphoblastic leukemia without clinically diagnosed central nervous system infiltration: a novel DTI-ALPS method
METTL1 promotes neuroblastoma development through m7G tRNA modification and selective oncogenic gene translation
The snoRNA-like lncRNA LNC-SNO49AB drives leukemia by activating the RNA-editing enzyme ADAR1
Prognostic value of serum ammonia in critical patients with non-hepatic disease: A prospective, observational, multicenter study
Prognostic significance of CNSL at diagnosis of childhood B-cell acute lymphoblastic leukemia: A report from the South China Children’s Leukemia Group
METTL1 promotes Neuroblastoma development through m 7 G tRNA modification and selective oncogenic gene translation
METTL1/WDR4-mediated m7G tRNA modifications and m7G codon usage promote mRNA translation and lung cancer progression
Prognostic Value and Outcome for ETV6/RUNX1-Positive Pediatric Acute Lymphoblastic Leukemia: A Report From the South China Children’s Leukemia Group
Treatment barriers and clinical outcome of children with medulloblastoma in China: a report from the Chinese Children’s Cancer Group (CCCG)
Arsenic trioxide and all-trans retinoic acid suppress the expression of FLT3-ITD
LINC-15. OUTCOME OF CHINESE CHILDREN WITH MEDULLOBLASTOMA: A MULTI-CENTER EXPERIENCE WITH RISK-ADAPTED THERAPY